Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study. by Marshall, I et al.
Vol.:(0123456789) 
Journal of Neurology (2018) 265:1795–1802 
https://doi.org/10.1007/s00415-018-8903-y
ORIGINAL COMMUNICATION
Characterisation of tissue-type metabolic content in secondary 
progressive multiple sclerosis: a magnetic resonance spectroscopic 
imaging study
Ian Marshall1  · Michael J. Thrippleton1 · Mark E. Bastin1 · Daisy Mollison1 · David A. Dickie1,2 · 
Francesca M. Chappell1 · Scott I. K. Semple3 · Annette Cooper4 · Sue Pavitt5 · Gavin Giovannoni6 · 
Claudia A. M. Gandini Wheeler‑Kingshott7,8,9 · Bhavana S. Solanky7 · Christopher J. Weir10 · Nigel Stallard11 · 
Clive Hawkins12 · Basil Sharrack13 · Jeremy Chataway14 · Peter Connick1 · Siddharthan Chandran1 · for the MS‑
SMART Trialists
Received: 19 January 2018 / Revised: 7 May 2018 / Accepted: 9 May 2018 / Published online: 30 May 2018 
© The Author(s) 2018
Abstract
Proton magnetic resonance spectroscopy yields metabolic information and has proved to be a useful addition to structural 
imaging in neurological diseases. We applied short-echo time Spectroscopic Imaging in a cohort of 42 patients with sec-
ondary progressive multiple sclerosis (SPMS). Linear modelling with respect to brain tissue type yielded metabolite levels 
that were significantly different in white matter lesions compared with normal-appearing white matter, suggestive of higher 
myelin turnover (higher choline), higher metabolic rate (higher creatine) and increased glial activity (higher myo-inositol) 
within the lesions. These findings suggest that the lesions have ongoing cellular activity that is not consistent with the usual 
assumption of ‘chronic’ lesions in SPMS, and may represent a target for repair therapies.
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Introduction
Multiple sclerosis (MS) is a disabling neurological disease 
affecting some 2.5 million people worldwide (http://www.
mstru st.org.uk). There are currently no effective treatments 
for the progressive phases of MS when disability accu-
mulates irreversibly. In clinical trials of potential disease-
modifying therapies, the standard outcome measure is the 
Expanded Disability Status Scale (EDSS) [1]. In imaging 
studies, lesion load and brain atrophy are widely used bio-
markers. White matter lesions (WML) are visible on routine 
magnetic resonance imaging (MRI) sequences, and represent 
current or previous inflammatory activity. More advanced 
MRI methods enable estimation of myelin status through 
white matter connectivity and magnetisation transfer imag-
ing [2]. Complementary information on neuronal integrity 
is available from proton MR spectroscopy and spectroscopic 
imaging (MRSI) studies of brain metabolites.
A consistent finding of spectroscopic studies is that the 
level of the neuronal marker N-acetyl aspartate (NAA) is 
reduced in the normal-appearing white matter (NAWM) of 
patients compared with controls [3–5], and further reduced 
in WML [4, 6], although this latter finding may apply spe-
cifically to chronic rather than acute lesions [7]. In a lon-
gitudinal study, Obert et al. [8] found that NAA decreased 
in the NAWM of patients with secondary progressive MS 
(SPMS) and in the WML of patients with relapsing–remit-
ting MS (RRMS).
Other findings from these studies are that choline, a 
potential marker of myelin turnover, is increased in acute 
lesions relative to NAWM [6], and in acute WML and 
NAWM relative to WM in control subjects [7]. Raised lev-
els of myo-inositol, associated with glial activity, have been 
found in acute WML, chronic WML and NAWM relative 
to WM in controls [7], in grey matter (GM) and NAWM 
relative to controls [5], and in WML relative to NAWM [8]. 
Srinivasan et al. [7] found increased levels of glutamate, 
but not glutamine, in acute WML and NAWM relative to 
control WM.
The non-invasive nature of MRSI lends itself to use in 
longitudinal studies, both to monitor the natural progres-
sion of disease and in clinical trials of potential disease-
modifying treatments. One such trial is MS-SMART (http://
www.ms-smart .org), a 2-year, multicentre trial of three 
repurposed drugs for treatment of SPMS. Here, we report 
on MRSI measurements of brain metabolites made at the 
baseline time point of this trial. Using image segmentation 
and linear modelling we were able to investigate metabolite 
differences between tissue types.
Methods
111 patients with SPMS who had had no relapses within 
the previous 3  months gave informed consent to be 
recruited in our centre as part of the study. At baseline, 43 
patients (mean age 55 (standard deviation, SD 8) years; 
30 female and mean EDSS score 6.0 (SD 0.7)) underwent 
MRSI as part of an MRI examination at 3T (Siemens 
Verio, Siemens Healthcare, Erlangen, Germany) using a 
standard 12-channel matrix head coil. PD-T2-weighted and 
FLAIR structural scans were acquired parallel to the ante-
rior commissure–posterior commissure (ACPC) line with 
matrix 256 × 256, field of view (FOV) 250 × 250 mm and 
60 contiguous slices 3 mm thick. The sequence timings 
were TR/TE1/TE2 = 3050/31/82 ms (turbo factor 7) and 
TR/TI/TE = 9500/2400/124 ms (turbo factor 28) respec-
tively. A 3D inversion recovery prepared T1-weighted 
gradient echo scan (MPRAGE) was also acquired with 
matrix 256 × 256, field of view (FOV) 250 × 250 mm, 
160 sagittal slices 1  mm thick, flip angle 8°, TR/TI/
TE = 2400/1000/3 ms and parallel imaging acceleration 
factor 2.
Proton MRSI was carried out using a manufacturer-
supplied prototype with semi-LASER excitation [9] and 
TR/TE of 2000/43 ms. Data were acquired from a sin-
gle 10-mm-thick slice of spectroscopic voxels prescribed 
immediately above the lateral ventricles in the plane of 
the T2-weighted images (Fig. 1). Thus, the MRSI slice 
thickness extended through three adjacent T2-weighted 
images. The excitation volume was 120 mm × 120 mm. 
The spatial encoding matrix was 24 × 24 with elliptical 
k-space sampling, interpolated to 32 × 32 by the scanner, 
resulting in 1 mL spectroscopic voxels. Free induction 
decays consisted of 1024 samples with a dwell time of 
500 µs. Weak water suppression was applied, together with 
four 30-mm-thick saturation bands positioned to suppress 
scalp lipid signals.
Spectroscopic data were analysed in LCModel [10] 
using a spectral basis set matching the semi-LASER 
sequence, generated using simulation routines within the 
FID-A toolkit [11]. The LCModel results for NAA, cho-
line, creatine, myo-inositol and Glx (the sum of glutamate 
and glutamine) were multiplied by the scanner transmitter 
reference voltage to adjust for subject-specific loading of 
the head coil [12]. Finally, metabolite measurements were 
corrected for relaxation effects using literature values for 
T1, derived from NAWM in a group of RRMS and SPMS 
patients [7] to yield concentrations in Institutional Units.
Voxels were excluded from further analysis if they 
were judged to be not completely inside the brain or if 
the LCModel Cramer–Rao bounds (i.e., % standard devia-
tions) of the fitted spectra exceeded 20% for any metabolite 
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or 40% for myo-inositol [7]. Additionally, voxels judged by 
an experienced spectroscopist to have poor quality spectra 
(e.g., with grossly distorted baselines) were discarded.
The 3D T1-weighted and 2D FLAIR structural volumes 
were co-registered to the T2-weighted images and seg-
mented to generate tissue probability maps for cerebrospi-
nal fluid (CSF), GM, NAWM and WML using tools freely 
available in FSL (https ://fsl.fmrib .ox.ac.uk) and ANTS [13]. 
WML probability masks were automatically created based 
on a FLAIR signal intensity threshold chosen empirically to 
provide WML masks that optimised the correspondence to 
masks manually segmented by an experienced neuroradiolo-
gist. The tissue segmentation maps were resampled to MRSI 
resolution and summed over three adjacent slices to match 
the MRSI slice thickness, thereby determining the overall 
fractional tissue content corresponding to each spectrum.
Tissue probabilities were used to predict metabolite 
concentrations (and ratios with respect to creatine) in a lin-
ear mixed model in SAS Studio 3.5 (http://www.sas.com). 
Subjects were regarded as random effects (i.e. a random 
intercept model) to allow for within-subject correlation of 
voxels and so that we could look specifically at differences 
in metabolite levels between tissue types within subject. To 
avoid problems with the collinearity of NAWM and GM, 
we used the variables (NAWM + GM), (NAWM-GM) and 
WML in the regression. Thus, the model was
where the metabolite concentrations Cmet and the tissue 
probabilities (NAWM, GM and WML) have been meas-
ured for each voxel. The β coefficients, Intercept and sub-
ject effects are estimated by the model. The model fit was 
assessed by examining plots of residuals. We also ran an 
extended model that included the EDSS score as a vari-
able. 19(17) Patients had EDSS scores of 6.0(6.5), with the 
remaining six patients having scores in the range 4.0 to 5.5. 
Given that the data were so sparse for these latter values, we 
combined them with the patients having EDSS of 6.0, i.e., 
dichotomising the patients into two groups with EDSS ≤ 6.0 
and EDSS = 6.5.
Results
Image registration failed for one patient, who was removed 
from the analysis. In the remaining 42 patients, a total of 
5349 spectroscopic voxels were located wholly within brain 
tissue, of which 4558 (85%) passed the Cramer–Rao tests. 
916 (20%) of these voxels failed the visual test of spectral 
quality, leaving 3642 voxels (87 ± 17 per patient: range 
Cmet = Intercept + 훽1(NAWM + GM) + 훽2(NAWM − GM)
+ 훽3WML + (subject effect).
Fig. 1  Prescription of the MRSI scan showing (left) the semi-LASER excitation region with red outline and outer volume suppression regions 
with blue outlines; (right) angulation of the MRSI slice parallel to the AC–PC line immediately above the lateral ventricles
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33–116) in the final analysis. Tissue probabilities averaged 
across all accepted voxels were GM 31%, NAWM 56% and 
WML 3%, with the balance being CSF. An example of tis-
sue segmentation is shown in Fig. 2. The overall mean (SD) 
linewidth of all accepted spectra was 7.0 (2.3) Hz. Repre-
sentative fitted spectra are shown in Figs. 3 and 4.
Tissue-specific metabolite concentrations determined 
from the linear mixed model (disregarding EDSS score) are 
given in Table 1 and Fig. 5. Several previous studies [3, 6, 
14, 15] have reported ratios with respect to creatine and we 
have included these in Table 2 and Fig. 6. All metabolite 
concentrations and ratios are reported as mean (standard 
error).
We found that the level of choline was higher in NAWM 
than GM (196 (5) vs 147 (5) Institutional Units) whereas 
creatine was lower (809 (14) vs 858 (15)) as was Glx (1164 
(21) vs 1392 (24)) (p < 0.001 for all these comparisons). 
There were no significant differences in myo-inositol level 
between GM and NAWM, nor in NAA levels between any 
of GM, NAWM and lesions.
Choline, creatine and myo-inositol levels were all signifi-
cantly (p < 0.001) higher in WML compared with NAWM 
and GM. There were no significant differences in NAA or 
Glx levels between WML and NAWM, but Glx was lower 
in WML than in GM (p = 0.002).
Significant differences were found between all three tissue 
types for all the metabolite ratios with respect to creatine. 
Specifically, despite the higher creatine in WML compared 
with NAWM (Table 1), the ratios choline/creatine and myo-
inositol/creatine are also higher in WML than NAWM. On 
the other hand, the ratios NAA/creatine and Glx/creatine are 
lower in WML than NAWM, whereas NAA and Glx were 
individually not different between WML and NAWM.
In the ancillary mixed model with dichotomised EDSS 
scores, we found no significant differences with respect 
to EDSS for any metabolite or metabolite ratio (all p 
values > 0.3).
Discussion
Short-TE MRSI coupled with tissue segmentation and lin-
ear modelling enabled estimation of brain metabolite levels 
in GM, NAWM and WML despite very few voxels having 
‘pure’ tissue content. Including subjects as random effects 
enabled us to focus on metabolite differences between tis-
sue types. Our findings for NAWM compared with GM are 
consistent with the literature except that we found no signifi-
cant difference in myo-inositol levels. Of particular interest 
is our finding that WML had higher choline, creatine and 
myo-inositol levels than did NAWM, suggesting ongoing 
abnormal metabolism in these lesions.
NAWM–GM differences
Our findings for the concentrations of choline, creatine and 
Glx in NAWM compared with GM are consistent with previ-
ous studies in healthy controls [12, 16, 17].
We found no significant difference in NAA level between 
NAWM and GM. Studies in control subjects have found 
NAA to be either lower or higher in GM than in WM, with 
a range from 15% lower to 46% higher being reported by 
Schuff et al. [16]. They speculated that these mixed find-
ings might in part be due to regional variations, the age of 
the participants, relaxation values or technical differences 
in acquisition.
Our finding of no significant difference between NAWM 
and GM levels of myo-inositol differs from Llufriu et al. 
[5] who found levels 50% higher in GM in a cohort of 59 
patients with MS of undisclosed subtype. Similarly, in an 
early single-voxel MRS study of healthy young controls, 
Michaelis et al. [12] found myo-inositol levels 30% higher 
in GM than WM. The different excitation scheme (STEAM 
rather than the usual PRESS or semi-LASER), shorter echo 
time (20 vs 43 ms) and mixed tissue content in that study 
may partly explain the disparate findings.
Fig. 2  MRSI voxel grid and tissue segmentations overlaid on the 
T2-weighted image for a representative patient. The spectroscopic 
excitation volume is shown with a red outline. Green shading indi-
cates NAWM and pale blue indicates WML
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WML–NAWM differences
Numerous studies have compared NAWM in MS patients 
with NAWM in control subjects, but relatively few have 
compared NAWM with WML. This is likely due to the 
difficulties of making MRS measurements in lesions of 
generally small size, irregular shape and low overall load. 
Cucurella et  al. [4] used a single 8 mL MRS voxel in 
each of 18 SPMS patients, placed either in predominately 
NAWM or predominately WML, finding that NAA was 
lower in WML than NAWM. Kapeller et al. [18] found 
reduced NAA and increased myo-inositol in WML relative 
to NAWM in a group of 32 patients with MS of undis-
closed subtype.
Using a mixed linear model we found no difference in 
NAA or Glx between NAWM and WML although the ratios 
NAA/cre and Glx/cre were respectively lower and higher 
in WML. As did Obert et al. [8], we found increased myo-
inositol in WML relative to NAWM.
Srinivasan et al. [7] used a custom single-voxel spectro-
scopic sequence designed to separate the heavily overlapped 
glutamate and glutamine components of the composite ‘Glx’ 
signal. In a mixed cohort of RRMS, primary and secondary 
progressive MS patients, they compared 12 chronic WML 
voxels with 17 NAWM voxels. They found that NAA, 
choline and glutamate were lower in chronic WML than 
NAWM. When including the signal from glutamine, there 
was no difference for the combined Glx, as we found in the 
present study.
Our finding of significantly higher levels of choline, 
creatine and myo-inositol in WML relative to NAWM sug-
gest higher membrane turnover, higher metabolic rate and 
increased glial activity, respectively. Inflammatory dis-
ease activity was low in this cohort, as evidenced by the 
Fig. 3  Spectra for the same patient as in Fig. 2 fitted by LCModel. Those shown in red passed the Cramer–Rao Bounds tests, whilst those shown 
in black did not. Spectra passing the CRB tests but judged to be of poor quality are shown in blue
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eligibility criteria and the structural MR brain features. The 
cohort can, therefore, reasonably be expected to have WML 
that were overwhelmingly non-recent. However, it would 
be simplistic to assume that the lesions were “chronic” (a 
neuropathological descriptor defined by apparent biologi-
cal inertness at post mortem examination) despite the phe-
notypic definition of “secondary progressive MS”. Indeed, 
our findings suggest that non-recent WML in SPMS patients 
who are EDSS ≤ 6.5 (i.e., not EDSS 10 [dead]) exhibit ongo-
ing cellular activity that is not consistent with the pathologi-
cal definition of “chronic”, and may represent a targetable 
substrate for repair therapies.
General points
A strength of our study is that the study group comprised 
a well-characterised cohort of SPMS patients with a nar-
row range of EDSS scores. A limitation is that there was 
no healthy control group and so it is difficult to know how 
‘normal’ the NAWM really is at this stage of the disease. 
The MS-SMART study is designed to compare two-year 
progression in four randomised groups (three candidate drug 
treatments and one placebo) and the main analysis will be 
Fig. 4  Representative examples of (left column, in red) spectra 
that passed the Cramer–Rao tests; (middle column, in black) spec-
tra that failed the Cramer–Rao tests; (right column, in blue) spectra 
that passed the Cramer–Rao tests but which were rejected at visual 
inspection. LCModel baselines are shown with dashed lines, and 
spectral fits with heavy lines. All spectra have the same scaling
Table 1  Principal metabolite concentrations in institutional units 
(mean ± std error) with respect to brain tissue type in 42 patients with 
SPMS
Significance of pairwise comparisons is shown as actual p values or 
as * (p < 0.01)
NAWM normal-appearing white matter, WML white matter lesions, 
GM grey matter
NAWM WML GM
Choline *
196 ± 5
263 ± 9
*
*
147 ± 5
Creatine *
809 ± 14
958 ± 32
*
*
858 ± 15
NAA 0.74
1449 ± 23
1469 ± 62
0.96
0.71
1447 ± 27
Myo-inositol *
463 ± 10
677 ± 24
0.50
*
469 ± 13
Glx 0.28
1164 ± 21
1220 ± 53
*
*
1390 ± 24
Fig. 5  Principal metabolite concentrations (mean ± std error) in insti-
tutional units with respect to brain tissue type. Columns are shaded 
grey, white and black to indicate GM, NAWM and WML, respec-
tively. NS: not significantly different. Further details in Table 1
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comparison of clinical status, structural features and metabo-
lites for each of the candidate drugs relative to placebo at the 
end of the trial. Interestingly, Obert et al. [8] have recently 
reported a reduction in NAWM NAA in 15 SPMS patients 
over the course of a 2-year study. Our finding that metabo-
lite values and ratios were not related to the EDSS scores 
at baseline in our study group is not surprising given the 
study design.
We used a single slice of MRSI, nominally placed imme-
diately above the lateral ventricles. Depending on the exact 
placement of the slice and the size and shape of the patient’s 
brain, the potential number of brain voxels varied. However, 
reduced numbers were mainly due to rejection based on the 
Cramer Rao bounds and visual quality assessment. The latter 
is time consuming and necessarily subjective, thus leading 
to interest in developing machine-learning approaches to 
spectral quality control [19].
We corrected the ‘raw’ metabolite measurements using 
assumed T1 relaxation times and for loading of the coil, 
resulting in institutional units. Other studies [3, 6, 15] 
have avoided these steps and reported ratios with respect 
to creatine, which was found or assumed to have a similar 
concentration in different tissues. In fact, creatine is often 
assumed to be a stable benchmark for hypothesis testing in 
MRS studies. Our work suggests that this is not necessarily 
the case, since taking ratios with respect to creatine changed 
our findings for NAA and Glx. We, therefore, advise caution 
for any MRS analysis based on the assumption of creatine 
being a stable reference.
The current analysis takes no account of the position of 
the voxels within the MRSI slice, and thus effectively aver-
ages tissue metabolite concentration values across the whole 
slice. Future methodological refinements could include 
regional analysis and absolute quantification of metabolites. 
Although the latter requires the use of calibrated phantoms 
and is time consuming, interpreting the measurements in 
terms of absolute concentrations (e.g., millimoles per litre) 
rather than Institutional Units should make it easier to com-
pare results between centres. The complex nature of MRS/
MRSI studies requires the detailed reporting of acquisition 
and analysis methods.
Conclusion
MS-SMART is one of the largest studies of SPMS, with 
440 patients recruited across 13 UK centres. Longitudinal 
changes in clinical status, structural features and metabolites 
will be investigated at the 2-year endpoint. Preliminary find-
ings at baseline in our MRSI sub-group show higher choline, 
creatine and myo-inositol in WML compared with NAWM, 
indicating higher myelin turnover, higher metabolic rate and 
increased glial activity respectively. These suggest that the 
lesions may have continuing, abnormal metabolism despite 
these patients being in a progressive phase of their disease 
during which lesions are often assumed to be ‘chronic’ and 
not active. This finding may have wider implications for the 
understanding of pathobiology of non-recent lesions in vivo, 
and for stratification for studies that evaluate repair thera-
pies. Adequately powered longitudinal studies are necessary 
to establish the usefulness of MRSI and other quantitative 
MRI techniques in monitoring disease progression and eval-
uating potential treatments.
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